Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097070 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
A Phase 2 study, sponsored by Myrexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01097070 is a Phase 2 study that has completed, run by Myrexis. The registered enrollment target is 35 participants.
The verdict
NCT01097070, a Phase 2 study, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
Interventions
- DRUG Bevirimat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097070
The ClinicalTrials.gov registry entry for NCT01097070 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevirimat is the first listed.
NCT01097070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01097070 about?
NCT01097070 is a clinical study titled "A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
What is the current status of trial NCT01097070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2008-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT01097070?
The interventions under investigation include: Bevirimat (DRUG).
Who is sponsoring clinical trial NCT01097070?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.